Madrigal Pharmaceuticals (MDGL) Net Cash Flow (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has reported Net Cash Flow for 17 consecutive years, with $60.6 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Net Cash Flow rose 2280.68% year-over-year to $60.6 million; the TTM figure through Jun 2026 stood at $100.3 million (up 132.52% YoY), while the FY2025 annual figure was $98.8 million, up 1834.78% from the prior year.
• Net Cash Flow advanced to $60.6 million in Q2 2026 per MDGL's latest filing, from $27.1 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $522.6 million in Q1 2024 and bottomed at -$261.9 million in Q3 2024.
• Historically, Net Cash Flow has averaged $14.2 million across 5 years, with a median of $6.0 million in 2022.
• Annual changes were most pronounced in 2023 — Net Cash Flow plunged 3729.49% — and 2026, when it surged 2280.68%.
• Madrigal Pharmaceuticals' Net Cash Flow stood at $272.2 million in 2022, then sank by 86.09% to $37.9 million in 2023, then tumbled by 450.41% to -$132.7 million in 2024, then climbed by 26.94% to -$96.9 million in 2025, then soared by 162.56% to $60.6 million in 2026.
• Business Quant data shows MDGL's Net Cash Flow at $60.6 million in Q2 2026, $27.1 million in Q1 2026, and -$96.9 million in Q4 2025.